Cdc42: An effector and regulator of ErbB1 as a strategic target in breast cancer therapy

Expert Review of Anticancer Therapy

Volumn 7, Issue 2, 2007, Pages 147-157

  Hirsch, Dianne S ^a   Wu, Wen Jin ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Breast cancer; c Cbl; Cdc42; ErbB1; ErbB1 degradation; Monoclonal antibody; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CBL PROTEIN; CETUXIMAB; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FARNESYL TRANS TRANSFERASE; GEFITINIB; GUANOSINE TRIPHOSPHATASE; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PANITUMUMAB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; PROTEIN CDC42; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TRASTUZUMAB; UNINDEXED DRUG;

ADJUVANT THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CELL TRANSFORMATION; CLINICAL TRIAL; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; PANCREAS CANCER; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN FUNCTION; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CDC42 GTP-BINDING PROTEIN; DRUG DELIVERY SYSTEMS; FEMALE; GENE TARGETING; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33847122119     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.2.147     Document Type: Review

References (100)

1. Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2006. CA Cancer J. Clin. 56, 106-130 (2006).
2. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann. Oncol. 16, 1569-1583 (2005).
3. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
4. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene amplification profiles from a population-based study. Proc. Natl Acad. Sci. USA 100, 10393-10398 (2003).
5. Levine PH, Steinhom SC, Ries LG, Aron JL. Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J. Natl Cancer Inst. 74, 291-297 (1985).
6. Wu M, Merajver SD. Molecular biology of inflammatory breast cancer: applications to diagnosis, prognosis, and therapy. Breast Dis. 22, 25-34 (2005).
7. Fitzpatrick SL, Brightwell J, Wittliff JL, Barrows GH, Schultz GS. Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels. Cancer Res. 44, 3448-3453 (1984).
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235, 177-182 (1987).
9. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712 (1989).
10. Press MF, Pike MC, Chazin VR et al. HER-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 53, 4960-4970 (1993).
11. Anderson WF, Matsuno R. Breast cancer heterogeneity: a mixture of at least two main types? J Natl Cancer Inst. 98, 948-951 (2006).
12. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol 2, 127-137 (2001).
13. Garrett TPJ, McKern NM, Lou M et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor a. Cell 110, 763-773 (2002).
14. Hynes NE, Lane HA. ERbB receptors and cancer: the complexity of targeted inhibitors. Nature Rev. Cancer 5, 341-354 (2005).
15. Garrett TP, McKern NM, Lou M et al. The crystal structure of truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 11, 495-505 (2003).
16. Cho HS, Mason K, Ramyar KX et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421, 756-760 (2003).
17. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16, 1647-1655 (1997).
18. Moscatello DK, Holgado-Madruga M, Godwin AK et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human rumors. Cancer Res. 55, 5536-5539 (1995).
19. Reist CJ, Archer GE, Kurpad SN et al. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res. 55, 4375-4382 (1995).
20. Wikstrand CJ, Hale LP, Batra SK et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55, 3140-3148 (1995).
21. Klapper LN, Glathe S, Vaisman N et al. The ErbB2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad. Sci. USA 96, 4995-5000 (1999).
22. Bacus S, Spector NL, Yarden Y. The era of ErbB-receptor-targeted therapies: advances toward personalized medicine. Pers. Med. 2, 301-315 (2005).
23. Kjoller L, Hall A. Signaling to Rho GTPases. Exp. Cell Res. 253, 166-179 (1999).
24. Tu S, Wu WJ, Wang J, Cerione RA. Epidermal growth factor-dependent regulation of Cdc42 is mediated by the Src tyrosine kinase. J. Biol, Chem. 278, 49293-49300 (2003).
25. Cerione RA. Cdc42: new roads to travel. Trends Cell Biol. 14, 127-132 (2004).
26. Waterman H, Yarden Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett. 490, 142-152 (2001).
27. Marmor MD, Yarden Y. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene 23, 2057-2070 (2004).
28. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103, 211-225 (2000).
29. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286, 309-312 (1999).
30. Waterman H, Levkowitz; G, Alroy I, Yarden Y. The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J. Biol. Chem. 274, 22151-22154 (1999).
31. Joazeiro CA, Weissman AM. RING finger proteins: mediators of ubiquitin ligase activity. Cell 102, 549-552 (2000).
32. Dikic I. Mechanisms controlling EGF receptor endocytosis and degradation. Biochem. Soc. Trans. 31, 1178-1181 (2003).
33. Peschard P, Park M. Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 3, 519-523 (2003).
34. Hirsch DS, Shen Y, Wu WJ. Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42. Cancer Res. 66, 3523-3530 (2006).
35. King CR, Kraus MH, Williams LT, Merlino GT, Pastan IH, Aaronson SA. Human tumor cell lines with EGF receptor gene amplification in the absence of aberrant sized mRNAs. Nucleic Acids Res. 13, 8477-8486 (1985).
36. Davidson NE, Gelmann EP, Lippman ME, Dickson RB. Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative breast cancer cell lines. Mol. Endocrinol. 3, 216-223 (1987).
37. Walker K, Olson MF. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr. Opin. Genet. Dev. 15, 62-68 (2005).
38. Ridley AJ. Rho: themes and variations. Curr. Biol. 6, 1256-1264 (1996).
39. Olson MF, Ashworth A, Hall A. An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. Science 269, 1270-1272 (1995).
40. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu. Rev. Cell Dev. Biol. 21, 247-269 (2005).
41. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev. Biol. 265, 23-32 (2004).
42. Wit WJ, Tu S, Cerione RA. Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation. Cell 114, 715-725 (2003).
43. Gampel A, Parker PJ, Mellor H. Regulation of epidermal growth factor receptor traffic by the small GTPase RhoB. Curr. Biol. 9, 955-958 (1999).
44. Wherlock M, Gampel A, Futter C, Mellor H. Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of RhoB GTPase. J. Cell Sci. 117, 3221-3231 (2004).
45. Schiller M. Coupling receptor tyrosine kinases to Rho GTPases-GEFs what's the link. Cell. Signal 18(11), 1834-1843 (2006).
46. Bernards A, Settleman J. GAP control: regulating the regulators of small GTPases. Trends Cell Biol. 14, 377-385 (2004).
47. DerMardirossian C, Bokoch GM. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol. 15, 356-363 (2005).
48. Lin Q, Fuji RN, Yang W, Cerione RA. RhoGDI is required for Cdc42-mediated cellular transformation. Curr. Biol. 13, 1469-1479 (2003).
49. Hart MJ, Eva A, Evans T, Aaronson SA, Cerione RA. Catalysis of guanine nucleotide exchange on the CDC42Hs protein by dbl oncogene product. Nature 354, 311-314 (1991).
50. Rossman KL, Der CL, Sondek J. GEF means go: turning on Rho GTPases with guanine nucleotide-exchange factors. Nat. Rev. Mol. Cell Biol. 6, 167-180 (2005).
51. Qiu RG, Chen J, McCormick F, Symons M. A role for Rho in Ras transformation. Proc. Natl Acad Sci. USA 92, 11781-11785 (1995).
52. Qiu RG, Chen J, Kirn D, McCormick F, Symons M. An essential role for Rac in Ras transformation. Nature 374, 457-459 (1995).
53. Qiu RG, Abo A, McCormick F, Symons M. Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation. Mol. Cell Biol. 17, 3449-3458 (1997).
54. Sahai E, Marshall CJ. Rho-GTPases and cancer. Nature Rev. Cancer 2, 133-142 (2002).
55. Downward J. Targeting Ras signalling pathways in cancer therapy. Nature Rev. Cancer 3, 11-22 (2003).
56. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast rumors, expression and mutation analyses and correlation with clinical parameters. Br. J. Cancer 87, 635-644 (2002).
57. Rihet S, Vielh P, Camonis J, Goud B, Chevillard S, Gunzburg J. Mutation status of genes encoding RhoA, Rac1, and Cdc42 GTPases in a panel of invasive human colorectal and breast tumors. J. Cancer Res. Clin. Oncol. 127, 733-738 (2001).
58. Fritz G, Just I, Kaina B. Rho GTPases are overexpressed in human tumors. Int. J. Cancer 81, 682-687 (1999).
59. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming onocogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 60, 5832-5838 (2000).
60. Cerione RA, Zheng Y. The Dbl family of oncogenes. Curr. Opin. Cell Biol. 8, 216-222 (1996).
61. Kourlas PJ, Strout MP, Becknell B et al. Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. Proc. Natl Acad Sci. USA 97, 2145-2150 (2000).
62. Engers R, Zwaka TP, Gohr L, Weber A, Gerharz C-D, Gabbert HE. Tiam1 mutations in human renal-cell carcinomas. Int. J. Cancer 88, 369-376 (2000).
63. Lin R, Bagrodia S, Cerione R, Manor D. A novel Cdc42Hs mutant induces cellular transformation. Curr. Biol. 7, 794-797 (1997).
64. Schnelzer A, Prechtel D, Knaus U et al. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 19, 3013-3020 (2000).
65. Wu WJ, Erickson JW, Lin R, Cerione RA. The γ-subunit of the coatomer complex binds Cdc42 to mediate transformation. Nature 405, 800-804 (2000).
66. Feng Q, Baird D, Peng X et al. Clone out of library-1 functions as an essential regulatory node for epidermal growth factor receptor-and Src-mediated cell growth. Nat. Cell Biol. 8, 945-956 (2006).
67. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 420, 629-635 (2002).
68. Yang W, Cerione RA. Cloning and characterization of a novel Cdc42-associated tyrosine kinase, ACK-2, from bovine brain. J. Biol. Chem. 272, 24819-24824 (1997).
69. Tu S, Cerione RA. Cdc42 is a substrate for caspases and influences Fas-induced apoptosis. J. Biol. Chem. 276, 19656-19663 (2001).
70. Wu WJ, Lin R, Cerione RA, Manor D. Transformation activity of Cdc42 requires a region unique to Rho-related proteins. J. Biol. Chem. 273, 16655-16658 (1998).
71. Ahn S-J, Chung K-W, Lee R-A et al. Overexpression of βPix-a in human breast cancer tissues. Cancer Lett. 193, 99-107 (2003).
72. de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med 8, S19-S26 (2002).
73. Hubbard SR. EGF receptor inhibition: attacks on multiple fronts. Cancer Cell 7, 287-288 (2005).
74. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59, 1935-1940 (1999).
75. Shin DM, Donato JN, Perez-Soler R et al. Epidermal growth Ector receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7, 1204-1213 (2001).
76. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
77. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett. 232(2), 123-138 (2006).
78. Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Adjuvant therapy with Trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11, 857-867 (2006).
79. Agus DB, Akita RW, Fox WD. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2, 127-137 (2002).
80. Xia W, Bacus S, Hedge P et al. A model of acquired resistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc. Natl Acad Sci. USA 103, 7795-7800 (2006).
81. Nahta R, Yuan LXH, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65, 11118-11128 (2005).
82. Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int. J. Cancer 108, 334-341 (2004).
83. Lu Y, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl Cancer Inst. 93, 1852-1857 (2001).
84. Balana ME, Labriola L, Salatino M et al. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 20, 34-47 (2001).
85. Camirand A, Zakikhani M, Young F, Pollak M. Inhibition of insulin-like growth factor-I receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) inhuman breast cancer cells. Breast Cancer Res. 7, R570-R579 (2005).
86. Jones HE, Goddard L, Gee JM. Insulin-like growth fictor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr. Relat. Cancer 11, 793-814 (2004).
87. Goetsch L, Gonzalez A, Leger O et al. A recombinant humanized anti-insulin-like growth factor receptor type I (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int. J. Cancer 113, 316-328 (2005).
88. Jo M, Thomas KS, Marozkina N et al. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activaty of urokinase-type plasminogen activator. J. Biol. Chem. 280, 17449-17457 (2005).
89. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidyinositol 3′-kinase/AKT pathway signaling. Clin. Cancer Res. 9, 4340-4346 (2003).
90. Karp JE, Lancet JE. Targeting the process of farnesylation for therapy of hematologic malignancies. Curr. Molec. Med. 5, 643-652 (2005).
91. Head JE, Johnston SRD. Protein farnesyltransferase inhibitors. Expert Opin. Emerg. Drugs 8, 163-178 (2003).
92. Sebti SM, Adjei AA. Farnesyltransferase inhibitors. Semin. Oncol. 31(1 Suppl. 1), 28-39 (2004).
93. Walker K, Olson MF. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr. Opin. Genet. Dev. 15, 62-68 (2005).
94. Miller SC, Mitchison TJ. Synthesis and phenotypic screening of a guanine-mimetic library. Chembiochem 5, 1010-1012 (2004).
95. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl Acad. Sci. USA 101, 7618-7623 (2004).
96. Citri A, Alroy I, Rubin SLC et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J. 21, 2407-2417 (2002).
97. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
98. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
99. Murphy N, Miller E, Lee CS. Gene expression profiling in breast cancer: towards individualizing patient management. Pathology 37, 271-277 (2005).
100. Simpson P, Reis-Filho JS, Gale T, Lakhani SR, Molecular evolution of breast cancer. J. Path. 205, 248-254 (2005).